Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
An Open-Label Study Investigating the 5-HT2A Receptor Occupancy of Remlifanserin (ACP-204) With the PET Radioligand [18F]Altanserin in Healthy Male Participants.
Journal: Clinical pharmacology in drug development
Published: April 03, 2026
Population pharmacokinetics of remlifanserin (ACP-204), a serotonin 2A receptor inverse agonist.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: December 19, 2025
Adjunctive Pimavanserin in Patients with Major Depressive Disorder: Combined Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Studies.
Journal: Psychopharmacology bulletin
Published: November 07, 2022
Exposure-response Modeling From the CLARITY Trial of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder.
Journal: Clinical pharmacology in drug development
Published: April 22, 2022
Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study.
Journal: International clinical psychopharmacology
Published: August 18, 2020
Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study.
Journal: Journal of affective disorders
Published: April 28, 2020
Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY.
Journal: The Journal of clinical psychiatry
Published: April 24, 2020
Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis.
Journal: Depression and anxiety
Published: October 30, 2019
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY).
Journal: The Journal of clinical psychiatry
Published: May 24, 2019
Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD.
Journal: European child & adolescent psychiatry
Published: July 19, 2017
Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Published: July 03, 2017
Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses.
Journal: Journal of clinical psychopharmacology
Published: October 14, 2014
Last Updated: 09/26/2026